PREVALENCE AND CLINICAL CHARACTERISTICS OF ELECTROLYTE DISORDERS IN PARANEOPLASTIC SYNDROME IN LUNG CANCER PATIENTS AT THAI BINH PROVINCIAL GENERAL HOSPITAL

Thị Thu Hiền Hà, Thị Minh Phượng Bùi

Main Article Content

Abstract

Objective: To determine the prevalence and clinical characteristics of electrolyte disorders (hyponatremia, hypercalcemia) in lung cancer patients at Thai Binh Provincial General Hospital. Study Subjects and Methods: A cross-sectional descriptive study on 44 lung cancer patients treated at Thai Binh General Hospital. The patients were tested for serum sodium and calcium levels, and the relationship with clinical characteristics was analyzed. Results: The prevalence of hyponatremia was 18.2%, and hypercalcemia was 6.8%. Hyponatremia was significantly associated with tumor size (>7 cm, p = 0.03). Hypercalcemia was more common in patients over 60 years old (p = 0.032) and those with a history of smoking. Conclusion: Electrolyte disturbances are common in lung cancer patients, especially in those with large tumors and a history of smoking.

Article Details

References

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424.
2. Bộ Y tế, Viện Nghiên cứu Phòng chống Ung thư. Báo cáo tình hình ung thư tại Việt Nam năm 2018. Nhà xuất bản Y học, 2019.
3. Johnson BE. Paraneoplastic syndromes in lung cancer. Semin Oncol. 2004;31(6):1-8.
4. Berardi R, Rinaldi S, Santoni M, et al. Paraneoplastic syndromes in lung cancer: Diagnostic and management implications. J Thorac Dis. 2018;10(8):4654-4665.
5. Hanna N, Johnson DH. Systemic effects of lung cancer. J Natl Compr Canc Netw. 2006;4(1):25-31.
6. Schwartz GG, Skinner HG. Vitamin D status and cancer: New insights. Curr Opin Clin Nutr Metab Care. 2007;10(1):6-11.
7. Ellison DH, Berl T. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007;356(20):2064-2072.
8. Mundy GR, Edwards JR. PTH-related peptide (PTHrP) in hypercalcemia of malignancy. J Clin Invest. 2008;122(4):1345-1347.